about
Molecular flexibility in ab initio drug docking to DNA: binding-site and binding-mode transitions in all-atom Monte Carlo simulationsTandem mass spectrometry for characterization of covalent adducts of DNA with anticancer therapeuticsComparison of the binding stoichiometries of positively charged DNA-binding drugs using positive and negative ion electrospray ionization mass spectrometry.Infrared multiphoton dissociation in quadrupole ion traps.The role of encapsulation by β-cyclodextrin in the interaction of raloxifene with macromolecular targets: a study by spectroscopy and molecular modeling.Epigenetic changes induced by curcumin and other natural compounds.Transcription factor decoy (TFD) in breast cancer research and treatment.Photodissociation mass spectrometry: new tools for characterization of biological molecules.DNA damage and inhibition of akt pathway in mcf-7 cells and ehrlich tumor in mice treated with 1,4-naphthoquinones in combination with ascorbate.pH luminescence switch, DNA binding and photocleavage, and cytotoxicity of a dinuclear ruthenium complex.Structure-activity relation for synthetic phenoxazone drugs: evidence for a direct correlation between DNA and pro-apoptotic activity.Albendazole as a promising molecule for tumor control.DNA-metallodrugs interactions signaled by electrochemical biosensors: an overview.Indirect readout in drug-DNA recognition: role of sequence-dependent DNA conformation.Comparison of MS/MS methods for characterization of DNA/cisplatin adducts.Circular dichroism spectroscopic studies reveal pH dependent binding of curcumin in the minor groove of natural and synthetic nucleic acids.Binding of Cu(II) complexes of oxicam NSAIDs to alternating AT and homopolymeric AT sequences: differential response to variation in backbone structure.Structural and energetic insights into sequence-specific interaction in DNA-drug recognition: development of affinity predictor and analysis of binding selectivity.Determination of helix orientations in a flexible DNA by multi-frequency EPR spectroscopy.Probing the intermolecular interactions into serum albumin and anthraquinone systems: a spectroscopic and docking approach.Exploring the interaction of phenothiazinium dyes methylene blue, new methylene blue, azure A and azure B with tRNAPhe: spectroscopic, thermodynamic, voltammetric and molecular modeling approach.Bimetallic Ru(ii) and Os(ii) complexes based on a pyrene-bisimidazole spacer: synthesis, photophysics, electrochemistry and multisignalling DNA binding studies in the near infrared region.Synthesis, antitumor activity evaluation, and DNA-binding study of coumarin-based agents.Binding studies of the anti-retroviral drug, efavirenz to calf thymus DNA using spectroscopic and voltammetric techniques.Understanding the Interactions of High-Mobility Group of Protein Domain B1 with DNA Adducts Generated by Platinum Anticancer Molecules Using In Silico Approaches.Study of the synthesis, antiproliferative properties, and interaction with DNA and polynucleotides of cisplatin-like Pt(II) complexes containing carcinogenic polyaromatic amines.131I-Evans blue: evaluation of necrosis targeting property and preliminary assessment of the mechanism in animal models.An insight of spirooxindole-annulated thiopyran – DNA interaction: spectroscopic and docking approach of these biological materialsNovel isothiacalothrixin B analogues exhibit cytotoxic activity on human colon cancer cells in vitro by inducing irreversible DNA damageInteraction of a Potential Anticancer Agent Hypericin and its Model Compound Emodin with DNA and Bovine Serum Albumin
P2860
Q24811382-96146FF1-314A-4BD9-8C07-831533E6DEC1Q28486298-F147BE71-578A-4A39-909D-51BAF1A991DBQ33207629-E5357532-EFD6-4E03-A3EE-E43C6107A415Q33419206-F2FEDEAE-5A55-4ABD-8117-40AB4873B66CQ33990468-C7DCCA82-E260-4024-BAF2-3CF80F9F7C10Q34180255-3E70B88F-630F-4417-809D-6AA4BF532E25Q35081110-1A189CCC-52C2-4F93-A0C3-E97A11F73A81Q37666151-54CBEFE2-3398-4AED-B629-6A4C5B6E396EQ38897164-256E3EC3-1687-4ADE-8E7C-DDC6B9341D8BQ39187037-7F0C6BC5-954F-4B17-A404-4D5BA114A202Q40630097-16A60800-250E-4254-8CC6-25D121460087Q41348862-19E5BD87-81A2-486C-BC8E-CA7DDABBD999Q41823463-3F172E6A-D925-4ADF-9ADD-ECB04AC27E50Q43042728-F8540C27-74E1-41B9-AB78-83152E05448CQ43249053-DA11192B-B1E1-489C-AD98-18D5AB7874C3Q45103618-D1E496A0-3BC7-46EE-A240-18E1937AF176Q45858014-E2FB2E29-F173-4DFB-8CE0-753DDF683A3BQ46970775-23CD1942-8088-4BD1-8385-ED9C226510B1Q47579759-FF5E94D5-A34F-4818-B6DD-EEB74A3D202BQ47704828-04F11C9C-40D6-490E-812C-192C400D0F5EQ48047061-62075586-4BCB-4CE7-8C24-00ED365C89A0Q48220340-F2C24F25-9D37-4E35-A886-A6A6C32EDF25Q48284645-ECAC0AD5-CD7F-4C9D-BF37-61A066EE9EEFQ50213507-5E80A8A2-3289-43FE-8C9F-33CA31E095ACQ51295860-94B0BFA0-070E-4831-B114-5CB2E3041943Q53251531-CA6EAE6A-8270-4BDF-A65F-5BF15B49A03EQ55342361-DE476AAE-24A1-43D9-B3A0-3C58811E62DCQ58146373-43B99655-9CD9-4BAB-B2A8-2A568A129567Q58762169-DAD2C9E9-81EF-4631-8F93-15AACEFA5112Q58765999-29CDA86D-FDF0-437F-BE45-CAE7F8B56CDB
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
DNA-binding of drugs used in medicinal therapies.
@ast
DNA-binding of drugs used in medicinal therapies.
@en
type
label
DNA-binding of drugs used in medicinal therapies.
@ast
DNA-binding of drugs used in medicinal therapies.
@en
prefLabel
DNA-binding of drugs used in medicinal therapies.
@ast
DNA-binding of drugs used in medicinal therapies.
@en
P356
P1476
DNA-binding of drugs used in medicinal therapies.
@en
P2093
Bischoff G
Hoffmann S
P304
P356
10.2174/0929867023371085
P577
2002-02-01T00:00:00Z